Author

Tyler Barker

Intermountain HealthcareORCID 0000-0001-7425-9582Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1 Assay:spatial transcriptomics· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Derrick S. Haslem· 2 shared Hanlee P. JiiD· 2 shared HoJoon LeeiD· 2 shared Lincoln D. NadauldiD· 2 shared Andrew SuiD· 1 shared Anuja SatheiD· 1 shared Bryce MoultoniD· 1 shared Christina M. Wood-Bouwens· 1 shared

Activity by Year

2020-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Derrick S. Haslem

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer Biologynpj Precision OncologyPeer-reviewedApr 6, 2025

The single-cell spatial landscape of stage III colorectal cancers

Andrew Su, HoJoon Lee, Minh Tran…·Terence Duane Rhodes

This study uses spatial single-cell analysis to identify 10 cell phenotypes in stage III colorectal cancers and links specific spatial features to recurrence risk.

14 citationstop 5%

humanspatial transcriptomics

𝕏 PostBluesky

GenomicsScientific ReportsPeer-reviewedMar 19, 2020

Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer

Li C. Xia, Paul Van Hummelen, Matthew A. Kubit…·Lincoln D. Nadauld

The paper identifies TP53 genomic deletions as a poor prognosis marker in Stage III colorectal cancer using a new low-coverage whole-genome sequencing protocol.

9 citations

humanwhole-exome sequencing

𝕏 PostBluesky